Navigation Links
Infinata Implements “Clear Quality” Initiative to Optimize Reliability and Usability of Data, Reports and Analysis for Biopharma and Wealth Management Solutions
Date:4/4/2013

Norwood, MA (PRWEB) April 04, 2013

Infinata, part of the Financial Times Group of companies, is a leading provider of business intelligence solutions including BioPharm Insight™, BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. Today the company announced the launch of its corporate-wide Clear Quality initiative to optimize reliability and usability of its cloud-based solutions.

With more than 250 individual quality checks and processes, Clear Quality formalizes Infinata’s commitment to ensuring every one of its hundreds of thousands of data points is as current and accurate as possible for three primary goals:

  •     Data Integrity – Underlying internal and external data sources are current and accurate, ensuring reliable reports and up-to-date analysis
  •     Consistency – Results and recommendations from diverse searches reach uniform conclusions and are presented in a familiar manner for a seamless user experience
  •     Accessibility – Our streamlined and intuitive interface is constantly refined to reduce the number of clicks from a customer’s inquiry to an actionable result

“Infinata was founded over a decade ago by data aggregation and integration experts,” said Ruth McHenry, Managing Director of Infinata. “As the big data requirements of global biopharmaceutical and financial services industries mature, simply providing data is no longer sufficient. Infinata stays ahead of this curve by innovating with services, features and analysis which provide practical answers based on trustworthy data rather than ambiguous facts and figures.”

Continued McHenry, “Clear Quality is a robust, formal and transparent commitment to customers who rely on Infinata solutions for the information edge they need to gain a competitive advantage and dominate their global markets.”

To learn more about Infinata’s solutions, visit http://www.infinata.com.

About Infinata, Inc.

Featuring a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services, Infinata provides personalized technology solutions to turn information into insight. Infinata is a part of Mergermarket, part of the Financial Times Group of companies and a division of Pearson plc.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10599354.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
5. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
6. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
7. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
8. Northwest Bio Implements Major Balance Sheet Clean-Up
9. Clinilabs Launches Research Volunteer Authentication Initiative Choosing Verified Clinical Trials to Stop Dual Enrollment in Clinical Trials
10. Strategic Approach for R&D Is Goal at National Photonics Initiative Event Co-Sponsored by SPIE
11. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... its Chairman and CEO, Jim Joyce . ... Conference last Saturday, Bill Gates warned world ... people than nuclear weapons. Mr. Gates expressed his concern, ... agencies, that scientific terrorists have access to the necessary ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell ... unaudited financial results for the third quarter and first ... 2016. Third Quarter of Fiscal 2017 Highlights ... fiscal 2017 increased by 18.6% to RMB200.9 million ($28.9 ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... Feb. 23, 2017 ... except per share data, unaudited)Three Months Ended December 31,Twelve ... Revenue $       ... 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  756025%297303(2)%Vimizim ...
Breaking Biology Technology:
(Date:2/3/2017)... 2017  Texas Biomedical Research Institute announced that its Board ... as the Institute,s new President and CEO. Dr. Schlesinger ... 2017. He is currently the Chair of the Department of ... Microbial Interface Biology at Ohio State University. "We ... and CEO of Texas Biomed," said Dr. James O. ...
(Date:2/1/2017)... 1, 2017 IDTechEx Research, a leading provider ... announces the availability of a new report, Sensors for Robotics: ... Continue Reading ... ... robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets and Forecasts ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):